193538-79-3

Basic information

• Product Name: 4-Pyridinecarbonyl chloride, 2-methoxy- (9CI)
• Synonyms: 4-Pyridinecarbonyl chloride, 2-methoxy- (9CI);2-Methoxyisonicotinoyl chloride
• CAS NO: 193538-79-3
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 171.58104
• Product Categories: ACIDHALIDE
• Mol File: 193538-79-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Pyridinecarbonyl chloride, 2-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarbonyl chloride, 2-methoxy- (9CI)(193538-79-3)
• EPA Substance Registry System: 4-Pyridinecarbonyl chloride, 2-methoxy- (9CI)(193538-79-3)

Safety Data

• Hazardous Substances Data: 193538-79-3(Hazardous Substances Data)

Upstream product

• 105596-63-2 2-methoxy-isonicotinic acid 

Downstream Products

• 1187669-32-4 2-bromo-1-(2-methoxypyridin-4-yl)ethanone 

Relevant articles and documents

A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing

A 256-compound library was evaluated in an anti-HIV screen to identify structural "mimics"of the fused tetracyclic indole compound 1 (IDC16) that conserve its anti-HIV activity without associated cytotoxicity. Four diheteroarylamide-type compounds, containing a common 5-nitroisobenzothiazole motif, were identified as active. In subsequent screens, the most potent compound 9 (1C8) was active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50's of 0.6 and 0.9 μM, respectively. Compound 9 also inhibited HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50's ranging from 0.9 to 1.5 μM. The CC50 value obtained in a cytotoxicity assay for compound 9 was >100 μM, corresponding to a therapeutic index (CC50/EC50) of approximately 100. Further comparison studies revealed that, whereas the anti-HIV activity for compound 9 and the parent molecule 1 are similar, the cytotoxic effect for compound 9 was, as planned, markedly suppressed.

NEW COMPOUNDS 578

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT

Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.